The first of a class of calcimimetics has been approved by the FDA for the treatment of hyperparathyroidism associated with renal failure and in patients with parathyroid cancer.
These data provide further support that inflammation in general and periodontal disease more specifically are stroke risk factors.
High-dose atorvastatin protects patients with acute coronary syndrome from death and major cardiovascular events better than usual dose pravastatin.
Many therapeutic options now are available to prevent and treat osteoporosis, and consist of non-drug and drug or hormonal therapy. In just one decade, osteoporosis has been transformed from a disorder considered to be an inevitable and irreversible consequence of aging to a disorder in which there now is true therapeutic optimism. This article discusses the definition, epidemiology, and different causes of osteoporosis. Diagnostic studies, including bone densitometry, are reviewed as well as the various therapies.
Data supporting associations of subclinical thyroid disease with symptoms or adverse clinical outcomes or benefits of treatment are few.
Graded activity can return a patient to full employment faster than usual care.
Current rofecoxib use was associated with a higher risk of acute myocardial infarction or admission for heart failure compared to celecoxib.
Among patients with early, localized prostate cancer, the mortality rate accelerated after 15 years.